董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kurt Gustafson | 男 | Independent Director | 57 | 18.04万美元 | 未持股 | 2025-07-31 |
| Kevin Gorman | 男 | Independent Director | 66 | 39.23万美元 | 未持股 | 2025-07-31 |
| Raymond J. Deshaies | 男 | Director | -- | 未披露 | 未持股 | 2025-07-31 |
| Todd E. Simpson | -- | Director | -- | 未披露 | 未持股 | 2025-07-31 |
| Ellen G. Feigal | -- | Independent Director | -- | 未披露 | 未持股 | 2025-07-31 |
| Barbara Klencke | -- | Independent Director | -- | 未披露 | 未持股 | 2025-07-31 |
| Richard J. Ranieri | 男 | Independent Director | 73 | 23.43万美元 | 未持股 | 2025-07-31 |
| Bassil I. Dahiyat | 男 | Director, President and Chief Executive Officer | 55 | 499.98万美元 | 未持股 | 2025-07-31 |
| A. Bruce Montgomery | 男 | Lead Independent Director | 71 | 19.44万美元 | 未持股 | 2025-07-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Bart Jan Cornelissen | -- | Senior Vice President and Chief Financial Officer | -- | 未披露 | 未持股 | 2025-07-31 |
| Celia E. Eckert | -- | Senior Vice President, General Counsel and Corporate Secretary | -- | 未披露 | 未持股 | 2025-07-31 |
| Bassil I. Dahiyat | 男 | Director, President and Chief Executive Officer | 55 | 499.98万美元 | 未持股 | 2025-07-31 |
| John R. Desjarlais | 男 | Executive Vice President, Research and Chief Scientific Officer | 61 | 195.42万美元 | 未持股 | 2025-07-31 |
董事简历
中英对照 | 中文 | 英文- Kurt Gustafson
-
Kurt Gustafson，自2016年10月起担任公司董事和审计委员会主席，自2017年3月起担任薪酬委员会成员。2018年4月，董事会任命Gustafson先生担任董事会首席独立董事，根据Gustafson先生在年度会议上的连任而定。他目前担任Spectrum Pharmaceuticals， Inc.的首席财务官、首席会计官和执行副总裁。纳斯达克：SPPI。从2009年到2013年，他担任Halozyme Therapeutics， Inc.（纳斯达克股票代码：HALO）的首席财务官。从1991年到2009年，他在Amgen （Nasdaq： AMGN）工作，担任财务副总裁、Amgen International的首席财务官和财务主管等各种财务职务。在加入Amgen之前，他曾在芝加哥Laventhol & Horwath担任公共会计部门的审计人员。他目前是Xencor， Inc.（纳斯达克股票代码：XNCR）的董事会成员，这是一家临床阶段的生物制药公司，专注于发现和开发工程单克隆抗体，以治疗未满足医疗需求的严重和危及生命的疾病。Gustafson先生担任Xencor审计委员会主席。Gustafson先生持有芝加哥North Park大学会计学学士学位和加州大学洛杉矶分校工商管理硕士学位。
Kurt Gustafson,has been a director of the Company and Chair of the Audit Committee since October 2016 and a member of the Compensation Committee since March 2017. In April 2018 the Board of Directors appointed Mr. Gustafson as lead independent director of the Board of Directors, contingent and effective upon Mr. Gustafson's re-election at the Annual Meeting.He currently serves as chief financial officer, principal accounting officer and executive vice president of Spectrum Pharmaceuticals, Inc. Nasdaq: SPPI. From 2009 to 2013 he served as the chief financial officer of Halozyme Therapeutics, Inc. (Nasdaq: HALO). From 1991 to 2009 Mr. Gustafson worked at Amgen (Nasdaq: AMGN), holding various financial roles as vice president finance, chief financial officer of Amgen International and treasurer. Prior to joining Amgen, he worked in public accounting as staff auditor at Laventhol & Horwath in Chicago. Mr. Gustafson is currently a member of the Board of Directors of Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Mr. Gustafson serves as Chair of Xencor's Audit Committee. Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles. - Kurt Gustafson，自2016年10月起担任公司董事和审计委员会主席，自2017年3月起担任薪酬委员会成员。2018年4月，董事会任命Gustafson先生担任董事会首席独立董事，根据Gustafson先生在年度会议上的连任而定。他目前担任Spectrum Pharmaceuticals， Inc.的首席财务官、首席会计官和执行副总裁。纳斯达克：SPPI。从2009年到2013年，他担任Halozyme Therapeutics， Inc.（纳斯达克股票代码：HALO）的首席财务官。从1991年到2009年，他在Amgen （Nasdaq： AMGN）工作，担任财务副总裁、Amgen International的首席财务官和财务主管等各种财务职务。在加入Amgen之前，他曾在芝加哥Laventhol & Horwath担任公共会计部门的审计人员。他目前是Xencor， Inc.（纳斯达克股票代码：XNCR）的董事会成员，这是一家临床阶段的生物制药公司，专注于发现和开发工程单克隆抗体，以治疗未满足医疗需求的严重和危及生命的疾病。Gustafson先生担任Xencor审计委员会主席。Gustafson先生持有芝加哥North Park大学会计学学士学位和加州大学洛杉矶分校工商管理硕士学位。
- Kurt Gustafson,has been a director of the Company and Chair of the Audit Committee since October 2016 and a member of the Compensation Committee since March 2017. In April 2018 the Board of Directors appointed Mr. Gustafson as lead independent director of the Board of Directors, contingent and effective upon Mr. Gustafson's re-election at the Annual Meeting.He currently serves as chief financial officer, principal accounting officer and executive vice president of Spectrum Pharmaceuticals, Inc. Nasdaq: SPPI. From 2009 to 2013 he served as the chief financial officer of Halozyme Therapeutics, Inc. (Nasdaq: HALO). From 1991 to 2009 Mr. Gustafson worked at Amgen (Nasdaq: AMGN), holding various financial roles as vice president finance, chief financial officer of Amgen International and treasurer. Prior to joining Amgen, he worked in public accounting as staff auditor at Laventhol & Horwath in Chicago. Mr. Gustafson is currently a member of the Board of Directors of Xencor, Inc. (Nasdaq: XNCR), a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Mr. Gustafson serves as Chair of Xencor's Audit Committee. Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles.
- Kevin Gorman
-
Kevin Gorman博士于2017年4月加入我们的董事会。他拥有超过26年的生命科学业务经验，包括金融、业务开发和运营的高级职务。戈尔曼博士是NeurocrineBiosciences，Inc.的创始人。他于2008年1月被任命为公司总裁兼首席执行官，此前曾担任执行Vice President兼首席运营官（2006年9月以来），以及执行Vice President兼首席商务官兼业务发展高级副总裁。他自2008年1月起在董事会任职。从1990年到1993年，Gorman博士是Avalon Medical Partners，L.P.的负责人，他负责该公司和其他几家生物技术公司的早期创立，如OnyxPharmaceuticals，Inc.、Metra Biosystems，Inc.、Idun Pharmaceuticals，Inc.和ARIADPharmaceuticals，Inc.。Gorman博士在加州大学洛杉矶分校（University of California，Los Angeles）获得免疫学博士学位和金融学工商管理硕士学位，并在洛克菲勒大学（Rockefeller University）做了进一步的博士后培训。
Kevin Gorman,joined Board of Directors in April 2017. He has more than 26 years in the life science business including senior roles in finance, business development and operations. Dr. Gorman is a founder of Neurocrine Biosciences, Inc. He was appointed President and Chief Executive Officer of the Company in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University. - Kevin Gorman博士于2017年4月加入我们的董事会。他拥有超过26年的生命科学业务经验，包括金融、业务开发和运营的高级职务。戈尔曼博士是NeurocrineBiosciences，Inc.的创始人。他于2008年1月被任命为公司总裁兼首席执行官，此前曾担任执行Vice President兼首席运营官（2006年9月以来），以及执行Vice President兼首席商务官兼业务发展高级副总裁。他自2008年1月起在董事会任职。从1990年到1993年，Gorman博士是Avalon Medical Partners，L.P.的负责人，他负责该公司和其他几家生物技术公司的早期创立，如OnyxPharmaceuticals，Inc.、Metra Biosystems，Inc.、Idun Pharmaceuticals，Inc.和ARIADPharmaceuticals，Inc.。Gorman博士在加州大学洛杉矶分校（University of California，Los Angeles）获得免疫学博士学位和金融学工商管理硕士学位，并在洛克菲勒大学（Rockefeller University）做了进一步的博士后培训。
- Kevin Gorman,joined Board of Directors in April 2017. He has more than 26 years in the life science business including senior roles in finance, business development and operations. Dr. Gorman is a founder of Neurocrine Biosciences, Inc. He was appointed President and Chief Executive Officer of the Company in January 2008 after having served as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He has served on the Board of Directors since January 2008. From 1990 until 1993 Dr. Gorman was a principal of Avalon Medical Partners, L.P. where he was responsible for the early stage founding of the company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.
- Raymond J. Deshaies
-
Raymond J. Deshaies是加州理工学院（Caltech）生物和生物工程系（BBE）的教授，他仍然是该校的外部附属机构。在加州理工学院任职期间，他还担任过BBE部门的执行官。2003年，Deshaies博士与人共同创立了Proteolix，该公司发现了一种用于治疗晚期多发性骨髓瘤患者的选择性蛋白酶体抑制剂carfilzomib，上市名称为KYPROLIS.他后来创立了Cleave Biosciences，专注于调节蛋白质稳态途径。Deshaies博士与人合著了170多篇科学论文，是蛋白质稳态和靶向蛋白质降解领域的国际领导者。他于2000年被任命为霍华德·休斯医学研究所的研究员，并分别于2011年和2016年入选美国艺术与科学院和美国国家科学院。Deshaies博士在康奈尔大学获得生物化学学士学位，在加州大学伯克利分校获得博士学位。他在伯克利和加州大学旧金山分校完成了博士后研究。
Raymond J. Deshaies,was a professor in the Division of Biology and Biological Engineering (BBE) at the California Institute of Technology (Caltech), where he remains an external affiliate. During his tenure at Caltech, he also served as executive officer of the BBE Division. In 2003, Dr. Deshaies co-founded Proteolix, which discovered carfilzomib, a selective proteasome inhibitor for the treatment of patients with advanced multiple myeloma, marketed as KYPROLIS. He later founded Cleave Biosciences, which was focused on modulating protein homeostasis pathways. Dr. Deshaies co-authored over 170 scientific papers and is an international leader in the fields of protein homeostasis and targeted protein degradation. He was named an investigator of the Howard Hughes Medical Institute in 2000 and elected to the American Academy of Arts and Sciences and the National Academy of Sciences in 2011 and 2016, respectively. Dr. Deshaies earned his B.S. in biochemistry from Cornell University and his Ph.D. from the University of California, Berkeley. He completed postdoctoral research at Berkeley and at the University of California, San Francisco. - Raymond J. Deshaies是加州理工学院（Caltech）生物和生物工程系（BBE）的教授，他仍然是该校的外部附属机构。在加州理工学院任职期间，他还担任过BBE部门的执行官。2003年，Deshaies博士与人共同创立了Proteolix，该公司发现了一种用于治疗晚期多发性骨髓瘤患者的选择性蛋白酶体抑制剂carfilzomib，上市名称为KYPROLIS.他后来创立了Cleave Biosciences，专注于调节蛋白质稳态途径。Deshaies博士与人合著了170多篇科学论文，是蛋白质稳态和靶向蛋白质降解领域的国际领导者。他于2000年被任命为霍华德·休斯医学研究所的研究员，并分别于2011年和2016年入选美国艺术与科学院和美国国家科学院。Deshaies博士在康奈尔大学获得生物化学学士学位，在加州大学伯克利分校获得博士学位。他在伯克利和加州大学旧金山分校完成了博士后研究。
- Raymond J. Deshaies,was a professor in the Division of Biology and Biological Engineering (BBE) at the California Institute of Technology (Caltech), where he remains an external affiliate. During his tenure at Caltech, he also served as executive officer of the BBE Division. In 2003, Dr. Deshaies co-founded Proteolix, which discovered carfilzomib, a selective proteasome inhibitor for the treatment of patients with advanced multiple myeloma, marketed as KYPROLIS. He later founded Cleave Biosciences, which was focused on modulating protein homeostasis pathways. Dr. Deshaies co-authored over 170 scientific papers and is an international leader in the fields of protein homeostasis and targeted protein degradation. He was named an investigator of the Howard Hughes Medical Institute in 2000 and elected to the American Academy of Arts and Sciences and the National Academy of Sciences in 2011 and 2016, respectively. Dr. Deshaies earned his B.S. in biochemistry from Cornell University and his Ph.D. from the University of California, Berkeley. He completed postdoctoral research at Berkeley and at the University of California, San Francisco.
- Todd E. Simpson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Ellen G. Feigal
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Barbara Klencke
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Richard J. Ranieri
-
Richard J. Ranieri，于2017年12月加入董事会。在担任此职务之前，他曾于2010年至2013年担任Dendreon Pharmaceuticals人力资源执行副总裁以及Sepracor，Inc.人力资源和行政执行副总裁。在其职业生涯的早期，Ranieri先生曾在Neurocrine Biosciences, Inc.、Genencor International和Smithkline Beecham担任行政职务。他获得了维拉诺瓦大学的学士学位，以及莱德大学的组织行为学硕士学位。
Richard J. Ranieri, joined Board of Directors in December 2017.Prior to this role he served as executive vice president, human resources at Dendreon Pharmaceuticals from 2010 to 2013 and executive vice president, human resources and administration at Sepracor, Inc. Earlier in his career, Mr. Ranieri served in executive positions at Neurocrine Biosciences, Inc., Genencor International, and Smithkline Beecham. He received a B.A. from Villanova University, and an M.A. in organizational behavior from Rider University. - Richard J. Ranieri，于2017年12月加入董事会。在担任此职务之前，他曾于2010年至2013年担任Dendreon Pharmaceuticals人力资源执行副总裁以及Sepracor，Inc.人力资源和行政执行副总裁。在其职业生涯的早期，Ranieri先生曾在Neurocrine Biosciences, Inc.、Genencor International和Smithkline Beecham担任行政职务。他获得了维拉诺瓦大学的学士学位，以及莱德大学的组织行为学硕士学位。
- Richard J. Ranieri, joined Board of Directors in December 2017.Prior to this role he served as executive vice president, human resources at Dendreon Pharmaceuticals from 2010 to 2013 and executive vice president, human resources and administration at Sepracor, Inc. Earlier in his career, Mr. Ranieri served in executive positions at Neurocrine Biosciences, Inc., Genencor International, and Smithkline Beecham. He received a B.A. from Villanova University, and an M.A. in organizational behavior from Rider University.
- Bassil I. Dahiyat
-
Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. - Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
- Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University.
- A. Bruce Montgomery
-
A. Bruce Montgomery，于2015年3月加入董事会。他目前是Avalyn Pharma（前身为Genoa Pharmaceuticals）的首席执行官和董事会成员，该公司是一家私营生物技术公司，他于2017年加入。2011年至2016年，他担任Cardeas Pharma的首席执行官和董事会成员，Cardeas Pharma是他于2010年创立的一家私营生物技术公司。2006年8月至2011年5月，Montgomery博士担任吉利德科学公司高级副总裁，在此之前，曾在Corus Pharma担任六年的首席执行官，Corus Pharma是他创立的一家专业生物技术公司，该公司于2006年被Gilead收购。在吉利德期间，Montgomery博士成功地领导了Cayston（氨曲南）的开发，作为囊性纤维化患者的治疗方法。Montgomery博士还曾在PathoGenesis Corporation担任研发执行副总裁，直到2000年被Chiron Corporation收购。他曾担任ZymoGenetics，Inc.的董事会成员，目前是Alder Biopharmaceuticals和Cytodyn，Inc.的董事会成员。Montgomery博士是一名董事会认证的内科医生和肺科医生。
A. Bruce Montgomery,joined Board of Directors in March 2015. He is currently Chief Executive Officer and a member of the board of directors of Avalyn Pharma formerly Genoa Pharmaceuticals, a private biotechnology company which he joined in 2017. From 2011 to 2016 he was Chief Executive Officer and a member of the board of directors of Cardeas Pharma, a private biotechnology company that he founded in 2010. From August 2006 to May 2011 Dr. Montgomery served as Senior Vice President of Gilead Sciences, Inc. and prior to that, served for six years as Chief Executive Officer of Corus Pharma, a specialized biotechnology company that he founded, which was acquired by Gilead in 2006. While at Gilead, Dr. Montgomery successfully led the development of Cayston (aztreonam) as a treatment for cystic fibrosis patients. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. He has served as a board member for ZymoGenetics, Inc. and is currently on the board of Alder Biopharmaceuticals and Cytodyn, Inc. Dr. Montgomery is a board certified internist and pulmonologist. Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major (Merck Award)), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle. - A. Bruce Montgomery，于2015年3月加入董事会。他目前是Avalyn Pharma（前身为Genoa Pharmaceuticals）的首席执行官和董事会成员，该公司是一家私营生物技术公司，他于2017年加入。2011年至2016年，他担任Cardeas Pharma的首席执行官和董事会成员，Cardeas Pharma是他于2010年创立的一家私营生物技术公司。2006年8月至2011年5月，Montgomery博士担任吉利德科学公司高级副总裁，在此之前，曾在Corus Pharma担任六年的首席执行官，Corus Pharma是他创立的一家专业生物技术公司，该公司于2006年被Gilead收购。在吉利德期间，Montgomery博士成功地领导了Cayston（氨曲南）的开发，作为囊性纤维化患者的治疗方法。Montgomery博士还曾在PathoGenesis Corporation担任研发执行副总裁，直到2000年被Chiron Corporation收购。他曾担任ZymoGenetics，Inc.的董事会成员，目前是Alder Biopharmaceuticals和Cytodyn，Inc.的董事会成员。Montgomery博士是一名董事会认证的内科医生和肺科医生。
- A. Bruce Montgomery,joined Board of Directors in March 2015. He is currently Chief Executive Officer and a member of the board of directors of Avalyn Pharma formerly Genoa Pharmaceuticals, a private biotechnology company which he joined in 2017. From 2011 to 2016 he was Chief Executive Officer and a member of the board of directors of Cardeas Pharma, a private biotechnology company that he founded in 2010. From August 2006 to May 2011 Dr. Montgomery served as Senior Vice President of Gilead Sciences, Inc. and prior to that, served for six years as Chief Executive Officer of Corus Pharma, a specialized biotechnology company that he founded, which was acquired by Gilead in 2006. While at Gilead, Dr. Montgomery successfully led the development of Cayston (aztreonam) as a treatment for cystic fibrosis patients. Dr. Montgomery also served as Executive Vice President of Research and Development at PathoGenesis Corporation until its acquisition by Chiron Corporation in 2000. He has served as a board member for ZymoGenetics, Inc. and is currently on the board of Alder Biopharmaceuticals and Cytodyn, Inc. Dr. Montgomery is a board certified internist and pulmonologist. Dr. Montgomery received his B.S. in Chemistry (Magna cum Laude, Outstanding Chemistry Major (Merck Award)), and M.D. (Alpha Omega Alpha Honor Medical Society) from the University of Washington, Seattle.
高管简历
中英对照 | 中文 | 英文- Bart Jan Cornelissen
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Celia E. Eckert
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Bassil I. Dahiyat
Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University.- Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
- Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University.
- John R. Desjarlais
John R. Desjarlais， 他是哲学博士。他曾一直担任研究副总裁（2006年10月以来）。他于2001年7月加入公司，最初担任蛋白质工程董事。他负责公司所有方面的发现和研究，包括技术的发展、蛋白质和抗体工程和生产候选产品。加入之前，他曾担任Penn State大学的化学副教授（从1997年到2001年）。他持有Massachusetts大学的物理学学士学位，以及Johns Hopkins大学的生物物理学博士学位。他在加州大学伯克利分校（the Fisher Center Policy Advisory Board）进行博士后研究。他推到了公司的技术开发和工程工作5年以上，并参与公司的商业和知识产权战略的发展。
John R. Desjarlais, Ph.D. has served as Chief Scientific Officer since July 2014 and served as Vice President, Research from October 2006 to July 2014. In March 2016 Dr. Desjarlais was appointed Senior Vice President, Research and Chief Scientific Officer. He joined the Company in July 2001 initially serving as Director of Protein Engineering. Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of product candidates. Prior to joining, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University from 1997 to 2001. Dr. Desjarlais received a B.S. in Physics from the University of Massachusetts and holds a Ph.D. in Biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the Company's technology development and engineering efforts for over ten years and participated in the development of the Company's business and intellectual property strategies.- John R. Desjarlais， 他是哲学博士。他曾一直担任研究副总裁（2006年10月以来）。他于2001年7月加入公司，最初担任蛋白质工程董事。他负责公司所有方面的发现和研究，包括技术的发展、蛋白质和抗体工程和生产候选产品。加入之前，他曾担任Penn State大学的化学副教授（从1997年到2001年）。他持有Massachusetts大学的物理学学士学位，以及Johns Hopkins大学的生物物理学博士学位。他在加州大学伯克利分校（the Fisher Center Policy Advisory Board）进行博士后研究。他推到了公司的技术开发和工程工作5年以上，并参与公司的商业和知识产权战略的发展。
- John R. Desjarlais, Ph.D. has served as Chief Scientific Officer since July 2014 and served as Vice President, Research from October 2006 to July 2014. In March 2016 Dr. Desjarlais was appointed Senior Vice President, Research and Chief Scientific Officer. He joined the Company in July 2001 initially serving as Director of Protein Engineering. Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of product candidates. Prior to joining, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University from 1997 to 2001. Dr. Desjarlais received a B.S. in Physics from the University of Massachusetts and holds a Ph.D. in Biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the Company's technology development and engineering efforts for over ten years and participated in the development of the Company's business and intellectual property strategies.